Investors back $70M IPO for Kythera

Kythera Biopharmaceuticals raised $70.4 million after pricing 4.4 million shares at the high end of its IPO price range, a rare success for maiden biotech offerings. Shares will begin trading today as KYTH. The biotech's lead therapy, now in late-stage development, is aimed at eliminating chin fat. That may not be a big unmet medical need in the pharma world, but investors saw a big upside on demand if the drug can win approval. Bayer, partnered in Europe, plans to submit a marketing application next year. Story

Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.